CD28 and myeloid sarcoma: Given that immune activation outside of the CNS precedes dysfunction of the BBB and subsequent immune cell infiltration in MS, it is plausible that lowered CD28 expression on CD4+ TEM and CD8low TCM cells after cladribine treatment may contribute to the reduced migratory capacity of these cell subsets [36].